Novo Nordisk issues statement on illegal mass compounding and deceptive advertising by Hims & Hers

Summary by AI BETAClose X

Novo Nordisk has issued a statement condemning Hims & Hers for their illegal mass compounding and deceptive advertising of an unapproved semaglutide pill, warning of significant patient safety risks and vowing legal and regulatory action. The company highlighted that compounded semaglutide is not FDA-approved and may contain impurities, unlike their FDA-approved Wegovy pill, which is available nationwide in full supply and formulated with SNAC technology for oral absorption. This action by Hims & Hers contradicts recent standards of care from the American Diabetes Association and Obesity Association, which discourage the use of compounded GLP-1s due to safety, quality, and effectiveness concerns.

Disclaimer*

UK 100

Latest directors dealings